Patient-Centered Communication Tool Feasible for Seniors With Acute Myeloid Leukemia
Patients, caregivers scored higher on AML knowledge and perceived greater efficacy in communicating with oncologists.
Patients, caregivers scored higher on AML knowledge and perceived greater efficacy in communicating with oncologists.
Researchers sought to determine whether prolonged inhibition of exportin-1 would lead to antileukemic activity in an NPM1-mutated AML murine model.
Rezlidhia is a small molecule inhibitor of mutated IDH1.
Researchers sought to determine whether there was a relationship between methylation of the gene SLC22A3 and prognosis in different forms of AML.
Salvage chemotherapy before allogeneic transplant does not improve outcomes in relapsed/refractory acute myeloid leukemia, a phase 3 study suggests.
Neither a higher dose of daunorubicin nor a second induction cycle improved outcomes in fit patients with newly diagnosed acute myeloid leukemia.
Researchers sought to assess the geriatric assessment in hematology scale in older patients diagnosed with hematological malignancies.
Combination magrolimab, azacitidine, and venetoclax appears effective in patients with newly diagnosed acute myeloid leukemia.
Pivekimab sunirine plus azacitidine and venetoclax has demonstrated activity in patients with relapsed/refractory or newly diagnosed acute myeloid leukemia.
Olutasidenib is a small-molecule inhibitor of mutated IDH1.